SCHEMBL5115676

SCHEMBL5115676

N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)NCCN1CCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 3/20 0.58
NPSR1 Q6W5P4 3/20 0.58
HTR1A P08908 2/20 0.58
NFKB1 P19838 2/20 0.58
HTR2A P28223 2/20 0.58
HTR2C P28335 2/20 0.58
HTR2B P41595 2/20 0.58
KDM4E B2RXH2 2/20 0.58
ALDH1A1 P00352 2/20 0.58
CYP3A4 P08684 2/20 0.58
MAPT P10636 2/20 0.58
LMNA P02545 1/20 0.58
ADORA3 P0DMS8 1/20 0.58
ALOX15 P16050 1/20 0.58
TSHR P16473 1/20 0.58
SLC6A4 P31645 1/20 0.58
HTR7 P34969 1/20 0.58
MTOR P42345 1/20 0.58
PMP22 Q01453 1/20 0.58
KMT2A Q03164 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5772690 0.92 BLM (0.56) BLMNPSR1HTR1ANFKB1HTR2A
SCHEMBL15962425 0.86 SOS1 (0.59) BLMKDM4EMAPTLMNATSHR
SCHEMBL18305783 0.85 SOS1 (0.58) BLMKDM4EMAPTLMNATSHR
SCHEMBL20168582 0.84 HDAC8 (0.77) BLMNPSR1HTR1ANFKB1HTR2A
SCHEMBL5121693 0.84 NPSR1 (0.67) BLMNPSR1HTR1ANFKB1HTR2A
SCHEMBL29804259 0.84 HDAC8 (0.77) BLMNPSR1HTR1ANFKB1HTR2A
SCHEMBL20168578 0.84 HDAC8 (0.77) BLMNPSR1HTR1ANFKB1HTR2A
SCHEMBL5123150 0.82 HDAC8 (0.52) BLMNPSR1HTR1ANFKB1HTR2A
SCHEMBL10407441 0.80 NPSR1 (0.69) BLMNPSR1HTR1ANFKB1HTR2A
SCHEMBL10407439 0.80 NPSR1 (0.69) BLMNPSR1HTR1ANFKB1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439258-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD (CA) 2008-10-21 US disclosed
EP-1301487-B1 VIRAL POLYMERASE INHIBITORS BOEHRINGER INGELHEIM CA LTD (CA) 2006-11-22 EP disclosed
US-20040224955-A1 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2004-11-11 US disclosed
US-6794404-B2 BENZIMIDAZOLE DERIVATIVES BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2004-09-21 US disclosed
US-20030232816-A1 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2003-12-18 US disclosed
US-6479508-B1 INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-11-12 US disclosed
US-6448281-B1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-09-10 US disclosed
US-20020065418-A1 Inhibitors of hepatitis C virus replication; treatment of hepatitis C BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232816-A1 Viral polymerase inhibitors POLR2H, POLR2E, POLM BLM 1873/4885NPSR1 1532/4885HTR1A 2508/4885
US-20020065418-A1 Inhibitors of hepatitis C virus replication; treatment of hepatitis C HAVCR2, HCCS, ZC3HAV1 BLM 3226/4885NPSR1 959/4885HTR1A 1889/4885
US-20040224955-A1 Viral polymerase inhibitors POLR2H, POLR2E, POLM BLM 1873/4885NPSR1 1532/4885HTR1A 2508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.